{"url":"https://lda.senate.gov/api/v1/filings/01a68ce5-cfe2-4762-b5fe-e15ff9f5db66/","filing_uuid":"01a68ce5-cfe2-4762-b5fe-e15ff9f5db66","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2025,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/01a68ce5-cfe2-4762-b5fe-e15ff9f5db66/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stephen Roberts, Attorney & Agent for Filer","dt_posted":"2026-01-20T23:17:53-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Ave.","registrant_address_2":"Suite 300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401109270,"url":"https://lda.senate.gov/api/v1/registrants/401109270/","house_registrant_id":66858,"name":"TALLEY STRATEGIES LLC","description":null,"address_1":"300 New Jersey Ave.","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMBER TALLEY","contact_telephone":"+1 919-922-1473","dt_updated":"2026-07-30T12:58:37.953033-04:00"},"client":{"id":68590,"url":"https://lda.senate.gov/api/v1/clients/68590/","client_id":68590,"name":"TEVA PHARMACEUTICALS USA, INC.","general_description":"Pharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-08-21"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to pharmaceutical drug pricing (no specific legislation).","foreign_entity_issues":"Client is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., as disclosed on the lobbying registration, and as such would benefit from similar opportunities as Client.","lobbyists":[{"lobbyist":{"id":148905,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"TALLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to pharmaceutical drug pricing (no specific legislation).","foreign_entity_issues":"Client is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., as disclosed on the lobbying registration, and as such would benefit from similar opportunities as Client.","lobbyists":[{"lobbyist":{"id":148905,"prefix":null,"prefix_display":null,"first_name":"AMBER","nickname":null,"middle_name":null,"last_name":"TALLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}